Roche reports 8 percent third-quarter growth and Roche Holding stock costs EUR 420.53

Published on 10/22/2026 at 09:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month sales rose 6 percent at constant rates. Roche Holding stock costs EUR 420.53 on October 22, 2026, with 2026 targets confirmed.

Roche sales and guidance

Roche reported third-quarter sales growth of 8 percent on October 22, 2026.
First-nine-month sales reached CHF 46.5 billion, up 6 percent at constant exchange rates.
Roche Holding stock traded at EUR 420.53 at 9:19 a.m. CEST at Lang & Schwarz on October 22, 2026.
Roche confirmed mid-single-digit 2026 sales growth and high-single-digit core earnings-per-share growth.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 420.53 at Lang & Schwarz on October 22, 2026, at 9:19 a.m. CEST. GlobeNewswire reported on October 22, 2026, that third-quarter sales rose 8 percent in Swiss francs as Roche confirmed its 2026 outlook.

Sales growth reaches 8 percent

Roche said group sales for the first nine months of 2026 reached CHF 46.5 billion, up 6 percent at constant exchange rates but only 1 percent in Swiss francs. The third quarter delivered 7 percent growth at constant exchange rates, with currency effects easing during the period.

Reuters said the result exceeded a company compiled analyst estimate of CHF 15.75 billion, with quarterly sales reaching CHF 16.13 billion. Xolair sales were CHF 848 million, below the CHF 925 million estimate cited by Reuters.

What does the outlook mean?

The confirmed 2026 outlook calls for group sales growth in the mid-single-digit range at constant exchange rates and core earnings per share growth in the high-single-digit range. Roche also expects to increase its dividend in Swiss francs, giving the quarterly update a supportive operating message despite currency effects.

Three dated Roche developments

On September 30, 2026, Roche said fenebrutinib reduced relapses by 51 percent and 58 percent versus teriflunomide in two phase III multiple sclerosis studies. On October 1, 2026, Roche reported that giredestrant reduced the risk of disease progression or death by 44 percent in a phase III breast cancer study. On October 22, 2026, the company reported third-quarter sales growth of 8 percent in Swiss francs. These events are detailed in the Roche release.

Upcoming dates for shareholders

Roche scheduled a Berenberg Pharma CFO Series event for November 2, 2026, according to its investor calendar. The company also proposed Dr Christophe Weber for election at the Annual General Meeting on March 9, 2027, as stated in the October 22 release.

Stock trades at the latest quote

Roche's sales growth is broad, but the reported Swiss-franc increase remains below the constant-rate performance because currency movements still affect the translated figures. The next investor test is whether the confirmed outlook converts the current product momentum into stronger reported growth.

The stock was trading at EUR 420.53 at Lang & Schwarz on October 22, 2026, at 9:19 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.